
7 March 2022
The EMPOWER-Cervical 1 trial findings demonstrate a significant survival advantage with cemiplimab versus investigator’s choice of chemotherapy for women with recurrent or metastatic cervical cancer that has progressed after treatment with platinum-containing chemotherapy.